Acerus Pharmaceuticals Corp. (ASPCF) 股价，以美元计价

Acerus is a Canadian pharmaceutical company focused on the development, manufacture, marketing and distribution of innovative, branded products that improve the patient experience. Founded in 2008, Acerus has quickly grown into a fully integrated company with expertise in all stages of the pharmaceutical product lifecycle, and focus in the therapeutic areas of Men's Health (Urology) and Women's Health (Hormone Replacement Therapy). Acerus has global rights to NATESTO, a product utilizing our licensed nasal gel technology, is the first and only testosterone nasal gel approved in Canada, and available in the United States for replacement therapy in adult males diagnosed with hypogonadism. Acerus also markets ESTRACE in Canada, a product indicated for the symptomatic relief of menopausal symptoms. Acerus operates from a Mississauga-based office, and is listed on the Toronto Stock Exchange (TSX:ASP)